ICON Public Limited Company (ICLR) EPS Estimated At $1.48

July 16, 2018 - By Margaret Guttierez

ICON Public Limited Company (NASDAQ:ICLR) Logo

Analysts expect ICON Public Limited Company (NASDAQ:ICLR) to report $1.48 EPS on July, 26.They anticipate $0.17 EPS change or 12.98 % from last quarter’s $1.31 EPS. ICLR’s profit would be $79.61M giving it 23.19 P/E if the $1.48 EPS is correct. After having $1.42 EPS previously, ICON Public Limited Company’s analysts see 4.23 % EPS growth. The stock decreased 0.78% or $1.08 during the last trading session, reaching $137.27. About 226,912 shares traded or 1.18% up from the average. ICON Public Limited Company (NASDAQ:ICLR) has risen 38.08% since July 16, 2017 and is uptrending. It has outperformed by 25.51% the S&P500.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Coverage

Among 7 analysts covering Icon (NASDAQ:ICLR), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Icon had 10 analyst reports since January 19, 2018 according to SRatingsIntel. The firm has “Overweight” rating by KeyBanc Capital Markets given on Monday, June 18. The stock has “Buy” rating by Credit Suisse on Thursday, February 15. The rating was maintained by Credit Suisse on Tuesday, June 19 with “Outperform”. On Thursday, February 15 the stock rating was maintained by Mizuho with “Hold”. As per Tuesday, April 3, the company rating was downgraded by Evercore. Jefferies maintained the shares of ICLR in report on Thursday, February 15 with “Buy” rating. SunTrust maintained ICON Public Limited Company (NASDAQ:ICLR) on Monday, January 22 with “Buy” rating. The stock has “Buy” rating by Robert W. Baird on Thursday, February 15. Mizuho maintained the stock with “Hold” rating in Wednesday, January 24 report.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company has market cap of $7.38 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It has a 26.09 P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

ICON Public Limited Company (NASDAQ:ICLR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.